Entheon Biomedical (XCNQ:ENBI) Debt-to-Asset : 0.00 (As of Nov. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Debt-to-Asset?

Entheon Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Entheon Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Entheon Biomedical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Nov. 2023 was C$0.40 Mil. Entheon Biomedical's debt to asset for the quarter that ended in Nov. 2023 was 0.00.

Entheon Biomedical Debt-to-Asset Historical Data

The historical data trend for Entheon Biomedical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Debt-to-Asset Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Debt-to-Asset

Get a 7-Day Free Trial

Entheon Biomedical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Entheon Biomedical's Debt-to-Asset

For the Biotechnology subindustry, Entheon Biomedical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Debt-to-Asset falls into.

Entheon Biomedical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Entheon Biomedical's Debt-to-Asset for the fiscal year that ended in Nov. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.401
	=	0.00

Entheon Biomedical's Debt-to-Asset for the quarter that ended in Nov. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.401
	=	0.00

Entheon Biomedical (XCNQ:ENBI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Entheon Biomedical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines